2016 pharmaceutical giant suffered layoffs Sanofi suffered

[China Pharmaceutical network industry trends] the list of 15 pharmaceutical companies making money in 2016 has been published, which should have been a carnival However, according to the new research report, compared with last year, the pace of these 15 enterprises slowed down significantly, with a year-on-year growth rate of 4% Among them, Novartis, Sanofi, Gilead and AstraZeneca have seen their performance decline, which makes people sigh: This is really a tough 2016 (2016 pharmaceutical giant suffered layoffs Sanofi suffered a lot Photo source: Baidu pictures) obviously, the "flat" growth curve makes many employees directly worry about their own pockets and jobs EP vantage found that by the end of 2016, the number of employees of 11 pharmaceutical giants was 866179, with an overall decrease of 1% Heavy losses: Sanofi's total staff decreased by 8%, from 115631 at the beginning of the year to 106859 at the end of the year The layoff wave in 2016 is worthy of Sanofi The main reason for this is the pricing pressure under the control of medical cost and the impact of bio generic drugs Some analysts believe that due to the continued downturn in diabetes performance, the pressure on its spending has been on the horizon for a long time And Lilly and bringer ingelham took Lantus's biosimilars out of the Jianghu, which gave Sanofi a key blow In the end, Sanofi kicked off 2016 with 500 job cuts in France Since then, its U.S sales of diabetes and cardiovascular drugs have been cut by 20% Surprise increase: although its scale is not equal to that of other pharmaceutical giants, and its income is only in the middle and lower reaches, the increase of its employees has given us a little surprise In 2016, it added 2000 employees, reaching 30000 at the end of the year, an increase more than that of veteran Roche (3%) and Lilly (2%) Xiumeile, the king of medicine in hand, focuses on the research and development of new drugs in the fields of antiviral, neurology, immunology, oncology, kidney disease, women's health and so on Ebev's "follow the cloud" has its internal logic Li Lai Li Lai is one of the only three expansion enterprises In 2016, its number of employees increased by 2% to 41975 In fact, the figure of 2% is quite impressive In recent years, Lilly has experienced a period of pain with the expiration of the protection of tumor drug Gemzar, psychoactive drug Zyprexa, depression drug Cymbalta and osteoporosis drug Evista Last year, semagacestat, which is regarded as the star of the future for Alzheimer's treatment, was defeated, which made Lilly have to pay for it again with layoffs Now, the company is finally turning its losses into profits, making the employment figures look better In addition, AstraZeneca, Pfizer, GlaxoSmithKline and Johnson & Johnson are also in the process of layoffs, with fine-tuning of their staff size.